Taysha Gene Therapies Inc
TSHA
$4.74-2.67%
End of day · as of Oct 1, 2026, 7:16 PM ET
Mkt cap
$640.75M
EV/Sales
38.0
P/E ratio
N/A
FY2025 Revenue
$9.77M
EPS (TTM)
$-0.41
Gross Margin (FY2025)
N/A
Profit Margin (FY2025)
-1115.27%
Beta
1.02
Div yield
N/A
Sector
Healthcare
Taysha Gene Therapies Inc (TSHA) is a biotechnology company listed on US.
Latest reported TSHA revenue for 2025-12-31 was $9.8M. Net income was -$109.0M. Revenue was up 17.3% from 2024-12-31 to 2025-12-31. TSHA currently screens at market cap $640.7M.
Use this TSHA research hub for sector, financials, and filings — not a live tape.
Latest cached year on this hub. Full TSHA income, balance, and cash tables.
† Total Debt: Derived from long-term debt only (no total or short-term debt stored).
Taysha Gene Therapies Inc (TSHA) is a biotechnology company in the Healthcare sector.
Latest cached Taysha Gene Therapies Inc (TSHA) revenue for Dec 31, 2025 was $9.8M. Net income was -$109.0M. Statements: https://lician.com/financials/tsha
Taysha Gene Therapies Inc (TSHA) market capitalization is $640.7M on the latest cached snapshot.
Taysha Gene Therapies Inc (TSHA) cached previous close $4.87; day range $4.73 – $4.94; volume 3,098,017. Session quote: https://lician.com/quote/tsha
Taysha Gene Therapies Inc (TSHA) latest cached earnings event is "TSHA earnings" on Aug 11, 2026. Earnings calendar: https://lician.com/earnings
The latest cached TSHA filing is 8-K · Jun 25, 2026. Filings: https://lician.com/sec/tsha